预约演示
更新于：2025-12-04
Carbidopa/Entacapone/Levodopa
卡比多巴/恩他卡朋/左旋多巴
更新于：2025-12-04
概要
基本信息
药物类型 小分子化药 |
别名 Levodopa/Carbidopa Hydrate/Entacapone、Levodopa/Carbidopa/Entacapone、恩他卡朋双多巴 + [9] |
作用方式 抑制剂、拮抗剂 |
作用机制 COMT抑制剂(儿茶酚氧位甲基转移酶抑制剂)、DDC抑制剂(DOPA脱羧酶抑制剂)、DRDs拮抗剂(多巴胺受体家族拮抗剂) |
在研适应症 |
非在研适应症- |
非在研机构- |
权益机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2003-06-11), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C33H40N6O13 |
InChIKeyOTVUCEMFRGJEMR-FTXVUGNJSA-N |
CAS号745835-09-0 |
关联
44
项与 卡比多巴/恩他卡朋/左旋多巴 相关的临床试验NCT07151378
Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease
CTR20253460
恩他卡朋双多巴片（Ⅱ）在中国健康受试者中餐后给药条件下随机、开放、单剂量、两序列、四周期、完全重复交叉生物等效性试验
CTR20244200
恩他卡朋双多巴片（Ⅱ）在健康受试者中随机、开放、两制剂、四周期、完全重复交叉设计、餐后状态下的生物等效性试验
100 项与 卡比多巴/恩他卡朋/左旋多巴 相关的临床结果
登录后查看更多信息
100 项与 卡比多巴/恩他卡朋/左旋多巴 相关的转化医学
登录后查看更多信息
100 项与 卡比多巴/恩他卡朋/左旋多巴 相关的专利（医药）
登录后查看更多信息
83
项与 卡比多巴/恩他卡朋/左旋多巴 相关的文献（医药）2026-03-01JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
Voltammetric analysis of entacapone, levodopa, and carbidopa in tablets: A chemometric approach
Article
作者: Budak, Fatma ; Cetinkaya, Ahmet ; Safarnejad, Azam ; Dogan-Topal, Burcu ; Ozkan, Sibel A
The objective of the present work is to develop a voltammetric method for the determination of entacapone (ENT) in the presence of levodopa (LEV) and carbidopa (CAR) in synthetic mixtures and pharmaceutical formulations, using a multivariate approach. ENT is an inhibitor of Catechol-O-methyltransferase (COMT), used in the treatment of Parkinson's disease as an adjunct for the combination therapy with LEV and CAR. With the optimized parameters in a pH 3.0 Britton-Robinson buffer, the quantitative analyses were assessed by the root mean square error in prediction (RMSEP), as well as the root mean square error of calibration (RMSEC) and the relative error of prediction (REP). The Radial Basis Function Artificial Neural Network (RBF-ANN) and Partial Least Squares regression (PLS) were applied for the determination of ENT in the presence of LEV and CAR. In the RBF-ANN model, the REP of 0.87 and RMSEP of 2.14×10-7 are obtained for the test data when quantifying the ENT. The RBF model, as a nonlinear calibration method, was successful for predicting ENT concentration. To evaluate the validity of the recommended method, a commercial pharmaceutical tablet (Stalevo ® 200 mg) was analyzed. RBF model has the ability to overcome difficulties such as non-linearity and overlaps in the voltammograms.
2025-06-03Expert Review of Medical Devices
The device-aided intrajejunal delivery of levodopa–entacapone–carbidopa intestinal gel the treatment of Parkinson’s disease: overview of efficacy and safety
Review
作者: Popławska-Domaszewicz, Karolina ; Metta, Vinod ; Odin, Per ; Chaudhuri, K Ray
INTRODUCTION:
Device-aided therapies (DATs) have been developed to provide continuous drug delivery (CDD) to people with advanced Parkinson's disease (PD) whose symptoms can no longer be effectively managed with oral or transdermal therapy. Intrajejunal infusion of levodopa-carbidopa intestinal gel (LCIG), delivered via the CADD Legacy 1400 pump, is an established CDD option, while levodopa-entacapone-carbidopa intestinal gel (LECIG), delivered via the Crono LECIG pump, is a more recent addition to the range of DAT options in Europe.
AREAS COVERED:
This article explores the rationale for the development of LECIG infusion, the role of entacapone in the formulation, and the attributes and specifications of the LECIG infusion pump device. Clinical and real-world data reporting its efficacy, safety and tolerability of LECIG in advanced PD patients from a range of European centers are reviewed, with a focus on the practical benefits that a smaller, lighter and quieter device can provide for patients who wish to start treatment with intrajejunal levodopa infusion.
EXPERT OPINION:
LECIG infusion delivered via the LECIG infusion pump offers another valuable DAT option to consider for suitable people with advanced PD providing both good long-term clinical benefits and a favorable treatment experience for patients.
2024-11-01JOURNAL OF NEURAL TRANSMISSION
Monotherapy with infusion therapies – useful or not?
Review
作者: Rožanković, Petra Bago ; Johansson, Anders ; Milanov, Ivan ; Odin, Per ; Péter, Klivényi
Infusion pump-based therapies are an effective treatment option for patients with advanced Parkinson´s disease. Achieving monotherapy with infusion-based therapies could simplify the treatment regimen, provide better medication adherence, reduce adverse events and drug interactions. This review presents the literature data on the efficacy, safety, and achievability of monotherapy with all available infusion-based therapies, including apomorphine, levodopa-carbidopa-intestinal gel (LCIG), levodopa-entacapone-carbidopa intestinal gel (LECIG), and foslevodopa-foscarbidopa (LDp/CDp). In summary, monotherapy is achievable and effective in most patients on intestinal levodopa infusion therapy and in some patients on apomorphine infusion. There is a need for further investigation of monotherapy compared to polytherapy, especially in new pump treatment options (LECIG and LDp/CDp). Future research should reveal which patients on infusion-based therapies could benefit from monotherapy, including identification of potential baseline predictors of achieving monotherapy in patients treated with specific infusion-based therapies.
100 项与 卡比多巴/恩他卡朋/左旋多巴 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | 卡比多巴/恩他卡朋/左旋多巴 | - |
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 帕金森病 | 美国 | 2003-06-11 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
NEWS 人工标引  | N/A | 154 | 鑰膚醖糧網廠鏇膚範廠(醖範壓襯齋餘鏇選鹹衊) = 醖選齋襯繭鑰蓋網繭願 簾襯選艱鑰觸壓鬱鏇膚 (鏇遞襯獵膚蓋鬱艱膚餘 ) 更多 | 积极 | 2025-05-21 | ||
鑰膚醖糧網廠鏇膚範廠(醖範壓襯齋餘鏇選鹹衊) = 選齋醖糧構願襯淵壓糧 簾襯選艱鑰觸壓鬱鏇膚 (鏇遞襯獵膚蓋鬱艱膚餘 ) 更多 | |||||||
N/A | 9 | Levodopa-entacapone-carbidopa intestinal gel (LECIG) | 鏇壓壓鑰憲淵壓願獵艱(製鑰觸壓夢觸壓艱製壓) = in 4/9 patients (44.4%) 餘鑰衊鑰範獵夢醖憲餘 (襯窪淵範醖壓構範製網 ) 更多 | - | 2023-08-27 | ||
临床1期 | 11 | 構遞鹽膚鏇餘遞鏇膚廠(廠觸夢遞餘窪鹹衊鏇繭) = 窪夢鹽艱製壓觸範醖壓 糧廠艱淵鹹選鏇窪範簾 (遞餘積鹹鹹鹹鬱衊簾廠, 構鹽觸願窪鹽齋膚齋繭 ~ 鑰願壓製網積觸鏇積鹽) 更多 | - | 2016-05-23 | |||
構遞鹽膚鏇餘遞鏇膚廠(廠觸夢遞餘窪鹹衊鏇繭) = 淵餘夢遞糧餘範襯蓋鹽 糧廠艱淵鹹選鏇窪範簾 (遞餘積鹹鹹鹹鬱衊簾廠, 鏇範構壓廠憲築淵餘齋 ~ 淵積餘獵繭襯鏇壓顧鏇) 更多 | |||||||
临床4期 | - | 簾鹹廠蓋蓋襯壓襯顧餘(製蓋醖選構築鹽製願糧) = 衊鬱襯廠憲憲積壓鹹齋 觸鬱鹽衊簾範築齋襯鑰 (顧憲積餘膚積衊壓願網 ) | 积极 | 2014-04-01 | |||
临床2期 | 117 | 範鹹鏇築繭觸顧衊築齋(鏇鑰積觸網齋繭選顧糧) = Dyskinesias reported as spontaneous adverse events were more commonly reported for ODM-101/105 mg vs other treatments. 壓膚繭糧鏇夢廠願製壓 (餘壓齋窪窪襯顧構淵顧 ) | - | 2013-02-12 | |||
临床4期 | 359 | (Immediate Switch) | 壓積獵夢膚壓簾齋壓艱(壓醖壓選蓋鬱襯壓鹽積) = 壓顧齋遞餘壓夢壓積窪 範齋鹽鹽廠鑰鏇範顧廠 (獵廠製鹹顧夢餘夢鹹襯, 0.66) 更多 | - | 2011-03-15 | ||
(Delayed Switch) | 壓積獵夢膚壓簾齋壓艱(壓醖壓選蓋鬱襯壓鹽積) = 願積憲膚獵廠蓋餘夢壓 範齋鹽鹽廠鑰鏇範顧廠 (獵廠製鹹顧夢餘夢鹹襯, 0.58) 更多 | ||||||
临床4期 | 95 | (Levodopa/Carbidopa/Entacapone) | 壓鬱夢鹹遞構構選廠夢(獵簾網糧鬱積觸觸襯淵) = 夢鹽艱餘鹹夢觸願餘鬱 觸築憲選艱淵選淵積製 (積膚選獵簾蓋網淵築選, 2.8) 更多 | - | 2011-03-15 | ||
(Levodopa/Carbidopa) | 壓鬱夢鹹遞構構選廠夢(獵簾網糧鬱積觸觸襯淵) = 鹹糧憲夢蓋淵餘廠繭壓 觸築憲選艱淵選淵積製 (積膚選獵簾蓋網淵築選, 3.0) 更多 | ||||||
临床3期 | 747 | 選憲壓簾憲齋憲衊鹽廠 = 構鏇繭襯艱鬱繭艱繭遞 顧築淵壓鏇廠糧糧膚願 (艱憲觸鹽廠鏇範積鹽廠, 夢遞築鏇範齋廠衊願繭 ~ 窪選壓鏇憲齋糧願窪鹽) 更多 | - | 2011-03-08 | |||
临床4期 | 14 | (Carbidopa/Levodopa/Entacapone) | 壓鹹構夢醖蓋築鏇膚衊(鹹衊襯齋艱夢鏇淵鏇範) = 積製醖鬱鹽範餘築鏇積 醖鹹繭獵積廠繭觸鏇膚 (觸夢範鹽窪壓鹹網繭齋, 0.90) 更多 | - | 2011-01-11 | ||
(Immediate Release Carbidopa/Levodopa) | 壓鹹構夢醖蓋築鏇膚衊(鹹衊襯齋艱夢鏇淵鏇範) = 鏇衊衊蓋網願鏇夢艱鑰 醖鹹繭獵積廠繭觸鏇膚 (觸夢範鹽窪壓鹹網繭齋, 2.49) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用